logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Tentatively Approves Supernus Pharma's Epilepsy Drug Supernus

Supernus Pharmaceuticals, Inc (SUPN), a developer of products to treat central nervous system, Monday said it received a tentative approval letter from the Food & Drug Administration or FDA for its epilepsy drug Trokendi XR. The product is tentatively approved for use as recommended in the submitted and agreed-upon labeling. Trokendi XR formerly known as SPN-538 is a novel once-daily extended release formulation of topiramate.

"We will now submit the "Request for Final Approval" letter to the FDA based on which we expect to receive Final Approval and then launch our product, as anticipated, in the third quarter of 2013," said Jack Khattar, chief executive officer.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving sharply higher at the open, stocks continue to see notable strength in mid-day trading on Wednesday. Buying interest has waned from earlier in the session, however, leading the major averages to pull back well off their highs. Former Florida Gov. Jeb Bush and businessman Donald Trump top the list of Republican presidential candidates in a new CNN/ORC International poll, although both are well behind Hillary Clinton in potential general election matchups. Confusion refuses to die down in Europe even after crucial deadlines were missed and hapless Greeks stare into an uncertain future for their country, while other Europeans try to preserve the sanctity of the union and the euro.
comments powered by Disqus
Follow RTT